Tagged with focus

Artificial Intelligence With so many wild predictions being bandied around about AI’s potential to radically transform healthcare for the better, it is easy to lose sight of the fact that materialization of that dream will be far from easy. Indeed, the task a hand can seem quite formidable. Most pharma companies’ existing…

Artificial Intelligence As data and information proliferate at an exponential pace, many industries have turned to artificial intelligence to make sense of this information and deliver meaningful insights that can enhance performance. This is certainly the case for the healthcare sector, where the technology augurs nothing less than a paradigm shift towards…

Artificial Intelligence On the supply side, AI appears to herald the prospect of de-risking the drug discovery process and doing away with many of the traditional time-consuming approaches at a juncture when drug development had been becoming financially unsustainable and clinical research organisations (CROs) had been systematically failing to improve operational efficiency.…

Artificial Intelligence The AI in Life Sciences Market was valued at USD 902.1 million in 2019 by Mordor Intelligence and is projected to expand at an impressive 20 percent compound annual growth rate in the period 2020 to 2024. Yet despite the massive hype and enthusiasm around artificial intelligence’s propensity to positively…

Artificial Intelligence IBM Watson Health’s Director for Global Life Sciences & Go-To Market Leader for Europe & Asia Pacific Christina Busmalis gives her insights into how AI and greater utilisation of real-world evidence is shaping the global biopharmaceutical industry, including the tangible results she has seen so far, and the lengthy path…

Opinion Professor Jackie Hunter looks at why the pharmaceutical industry has been so slow to adopt artificial intelligence-based technologies and makes a prediction for the industry’s future, including a significantly increased amount of interplay between large technology and pharma companies.   The past two decades have seen an explosion of biomedical…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities involving companies with artificial intelligence/machine learning platforms and technologies and their application to healthcare companies.   Artificial Intelligence Advances in technologies, an incorporation of entrants from outside the industry and changing consumer…

Opinion Vishal Doshi looks at how AI is already revolutionising healthcare in Asia-Pacific and the work still to be done on the foundational elements – infrastructure, regulations, and the availability of Asia-specific data – to ensure AI can be effectively utilised to improve patient outcomes in the region.   Healthcare, manufacturing,…

Cannabis PharmaBoardroom’s new InFocus section examines the fast-growing and lucrative global medical cannabis market, touching on investment opportunities, regulatory hurdles, regional hotspots and more.   With cannabis and cannabinoid treatments increasingly accepted as legitimate and effective medicines for a wide variety of conditions from chronic pain to mental disorders and even…

Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI.   As Biopharma increases AI investments,…

Opinion Bayer’s Michael Levy examines how artificial intelligence (AI) can assist in both the routine and advanced analytical tasks involved in conducting pharmacovigilance and therefore better ensure the safety of pharmaceuticals and the health of patients.   Pharmacovigilance or Patient Safety aims to promote and protect the health and well-being of…

Opinion Pierre Meulien of the Innovative Medicines Initiative (IMI) discusses the potential impact that new technological innovations will have on the drug development process.   A more technologically integrated approach is required that looks more holistically at the patient as an individual Whether we call it “Personalised”, “Precision”, “Stratified”, or “Tailored”, the age…